Sanofi - 15 Year Stock Price History | SNY
Historical daily share price chart and data for Sanofi since 2011 adjusted for splits and dividends. The latest closing stock price for Sanofi as of June 16, 2026 is 44.05.
- The all-time high Sanofi stock closing price was 53.91 on March 06, 2025.
- The Sanofi 52-week high stock price is 52.68, which is 19.6% above the current share price.
- The Sanofi 52-week low stock price is 42.28, which is 4% below the current share price.
- The average Sanofi stock price for the last 52 weeks is 47.52.
| Sanofi Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 44.1247 | 45.6950 | 46.6614 | 41.3084 | 44.0500 | -4.06% |
| 2025 | 47.2919 | 43.7198 | 53.9080 | 42.7011 | 45.9129 | 4.93% |
| 2024 | 45.1872 | 43.5175 | 53.1006 | 39.5052 | 43.7560 | 1.09% |
| 2023 | 43.8543 | 41.0385 | 48.0433 | 37.5382 | 43.2825 | 6.71% |
| 2022 | 39.8351 | 40.8471 | 46.8933 | 31.1725 | 40.5611 | 0.47% |
| 2021 | 39.9464 | 37.8541 | 43.7159 | 35.2994 | 40.3717 | 7.00% |
| 2020 | 37.8735 | 37.9449 | 41.7521 | 28.4661 | 37.7299 | 0.38% |
| 2019 | 32.3924 | 30.8044 | 38.0796 | 29.3454 | 37.5855 | 20.47% |
| 2018 | 29.6465 | 29.6363 | 32.7665 | 26.4482 | 31.1997 | 6.06% |
| 2017 | 31.2659 | 27.1718 | 34.6235 | 26.1716 | 29.4173 | 9.82% |
| 2016 | 26.2460 | 26.8250 | 28.2383 | 24.3904 | 26.7876 | -1.19% |
| 2015 | 30.7197 | 28.0019 | 34.9488 | 26.3864 | 27.1111 | -3.37% |
| 2014 | 31.2941 | 30.7158 | 35.2423 | 27.3129 | 28.0573 | -11.86% |
| 2013 | 30.0029 | 27.4907 | 32.8941 | 25.9877 | 31.8316 | 17.11% |
| 2012 | 22.4443 | 20.3659 | 27.3243 | 19.1838 | 27.1809 | 35.98% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $114.048B | $49.347B |
| Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |